ICPAD 2018 – Presentations

 Day 1 - Wednesday 8 November

 
 Session 1: Pharmacological challenges of immunotherapeutics 
 Biomarker in immuno-oncology, are we close?
(Not yet available)
Josep María Piulats, MD, PhD
Catalan Institute of Oncology, Spain
 
 Abstract presentation 
 Correlation between nivolumab exposure and treatment outcome in NSCLC
Sander Bins
 #O1
   
 Session 2: Dose individualization approaches 
 Cytotoxic agents
Markus Jörger, MD, PhD
Cantonal Hospital, Switzerland
 
 Targeted agents and monoclonal antibodies
Joseph Ciccolini, PharmD, PhD
Aix-Marseille Université, France
 
 Using pharmacogenetics to improve drug therapy:
a 12 year experience with clinical implementation
(Not yet available)
Ron van Schaik, PhD, FACB
Erasmus Medical Centre, the Netherlands
 
 Abstract presentation 
 A pharmacometric framework for dose individualisation of sunitinib in GIST
Maddalena Centanni
#O2
 Therapeutic drug monitoring as a tool to reduce the occurrence of paclitaxel-associated peripheral neuropathy in patients with advanced NSCLC
(Not yet available)
Francis Ojara Williams
#O3
   

 Day 2 - Wednesday 9 November

 
 Session 3: Combination therapy – old school is becoming new school again 
 Immunotherapy of prostate cancer and urothelial cancer. Future directions
Winald Gerritsen, MD, PhD
Radboud University, the Netherlands
 
 Rationale for selecting combinations with immunotherapy
Howard Gurney, MBBS, FRACP
Westmead Hospital, Australia
 
   
 Session 4: Drug-Drug / Drug-Food / Drug-environmental interactions 
 Drug-Drug interactions with targeted oncolytics (in particular PPIs and TKIs)
Ron Mathijssen, MD, PhD
Erasmus Medical Centre, the Netherlands
 
 Pharmacotherapy of Comorbities: Cancer Patients with HIV/AIDS
Michelle Rudek, PharmD, PhD
Johns Hopkins University School of Medicine, USA
 
 Drug-drug interaction management with DDI-Predictor
Michel Tod, PharmD, PhD
Faculté de Médecine Lyon-Sud, University of Lyon, France
 
 Abstract presentation 
 Novel online drug-drug interaction resource reveals clinically relevant interactions in >20% of the searches
Stefanie Krens
#O5
 Food intervention to make therapy with pazopanib more patient friendly and affordable
Floor Lubberman
 #O6
   
 Session 5: Approaches to shorten phase II studies by the use of different read out endpoints 
 

The value of surrogate endpoints in the benefit-risk assessment of new drugs
Gabe Sonke, MD, PhD
Netherlands Cancer Institute, the Netherlands

 
 Clinical relevance of liquid biopsy in cancer patients
Catherine Alix-Panabières, PhD
University Medical Centre of Montpellier, France
 
 Abstract presentation 
 A Pharmacokinetic-Pharmacodynamic binding model of Bevacizumab to VEGF as a tool to optimize treatment
Apostolos Papachristos
 #O7
 A generalisable pharmacokinetic-pharmacodynamic (PKPD) model of savolitinib, a novel MET tyrosine kinase inhibitor, to explore extent and duration of target inhibition required for optimal efficacy across a range of tumour xenograft models
Rhys Jones
 #O8
   
 Session 6: PK/PD studies and new strategies 
 How studies can be optimized by simultaneous use of PK/PD outcome measurement?
Alwin Huitema, PharmD, PhD
Netherlands Cancer Institute, the Netherlands
 
 Abstract presentation 
 The relationship between busulphan AUC and the incidence of sinusoidal obstruction syndrome in haematopoietic stem cell transplants
Parth Upadhyay
#O9
 Translation from mouse to human of pharmacokinetic-pharmacodynamic modelling of biomarker response – learnings from the AstraZeneca Oncology portfolio
Rhys Jones
#10